BioCentury
ARTICLE | Clinical News

Microbiome play Seres reports more Phase I data

July 17, 2014 12:55 AM UTC

Seres Health Inc. (Cambridge, Mass.) reported Phase I data from 30 patients with recurrent Clostridium difficile infection (CDI) receiving the company's SER-109, an oral mixture of microbiome organisms. All 15 patients in the first cohort who received a single high dose of SER-109 achieved the primary endpoint of no recurrence of CDI through eight weeks post-dosing. In the second cohort of the open-label trial, 11 of 15 patients who received a single low dose of SER-109 achieved the primary endpoint. Seres, which said SER-109 was safe, reported interim data from the trial in January. ...